Varex Imaging Delivers 11% Revenue Growth In Q4 Fiscal 2025

Varex Imaging reported strong Q4 FY2025 results, with non-GAAP net income rising to $15.3 million ($0.37/sh) from $6.5 million ($0.16) a year earlier and revenue up 11% to $229 million, driven by a 5% increase in its Medical segment (CT tube demand) and a jump in Industrial sales to $77 million on cargo-systems momentum. The company ended the year with $155 million in cash and marketable securities and guided Q1 FY2026 revenue of $200–$215 million and non-GAAP EPS of $0.05–$0.25 (prior-year quarter: $200 million revenue, $0.07 EPS), signaling stable top-line expectations but a wide earnings range. Shares have traded between $6.67 and $16.93 over the past year and closed at $11.86, up 3.8%, reflecting improved profitability but a cautious near-term outlook.

Analysis

Varex Imaging reported solid fourth-quarter FY2025 results with non-GAAP net income rising to $15.3 million ($0.37/share) from $6.5 million ($0.16) a year earlier and total revenue increasing 11% to $229 million from $206 million. The stock closed at $11.86, up 3.76%, and the company’s 52-week trading range remains wide at $6.67–$16.93, reflecting recent volatility.

Performance was driven by the Medical segment, which produced $152 million (up 5% year-over-year) on strong global CT tube demand, while the Industrial segment climbed to $77 million from $61 million on sustained cargo-systems momentum; the company also finished the year with $155 million in cash and marketable securities. These drivers underpin the beat on profitability and give the company balance-sheet flexibility for operations or strategic actions.

Guidance for Q1 FY2026 calls for revenue of $200–$215 million (prior-year quarter: $200 million) and a wide non-GAAP EPS band of $0.05–$0.25 (prior-year $0.07), indicating near-term earnings uncertainty despite stable top-line outlook. Market signals are moderately positive (sentiment score ~0.45) with modest market-impact (0.35), suggesting investor optimism tempered by the wide EPS range and recent stock volatility.

Key Decisions for Investors

• Consider a targeted, size-conservative buy or add to core exposure to VREX to play sustained CT tube and cargo-system demand given improved non-GAAP profitability and a $155 million cash buffer
• Avoid materially increasing position size ahead of the Q1 FY2026 print because the company’s wide EPS guidance ($0.05–$0.25) creates near-term earnings uncertainty; reassess after the quarter
• Use downside protection (e.g., partial hedges or option collars) or scale-in orders to manage risk given the 52-week trading range of $6.67–$16.93 and recent intraday volatility
• Monitor upcoming Q1 indicators—actual revenue versus the $200–$215 million range, segment-level trends in CT tube demand and cargo systems, and any changes to cash deployment—to inform further positioning